Clinical Trial Results:
RiFL: Rifaxamin in Fatty Liver Disease.
Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)?
Summary
|
|
EudraCT number |
2010-021515-17 |
Trial protocol |
GB |
Global completion date |
24 Sep 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
03 Jan 2020
|
First version publication date |
03 Jan 2020
|
Other versions |
|
Summary report(s) |
IRAS EoT Form |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.